beta
IA Trial Radar

Mostrando estudos clínicos para Câncer de ovário realizados em: China, Zhejiang.

Posso ajudar você a encontrar estudos clínicos em locais específicos e fornecer insights clínicos relevantes sobre condições de saúde e tratamentos.

No modo avançado, acesse ferramentas poderosas de pré-seleção, visualizações interativas e alertas personalizados por e-mail sobre atualizações dos estudos.

Nossa ferramenta de busca suporta apenas o inglês. Para pesquisa e discussão em outros idiomas, use a IA Trial Radar acima ou selecione filtros de condições médicas e locais abaixo.
42 resultados
 
Status (Padrão)
Ainda Não Recrutando, Em Recrutamento, Ativo, Não Recrutando
×
 
Condição médica
Câncer de ovário
×
 
Locais
China, Zhejiang
×
 
Faixa etária
Criança, Idoso
×
 
Título do estudo
Status
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) (RAINFOL-01) NCT05579366
Em recrutamento
Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment NCT07285941
Em recrutamento
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma NCT05043922
Ativo, não recrutando
TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients NCT07480785
Em recrutamento
Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer NCT04518501
Em recrutamento
Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC NCT06341907
Em recrutamento
A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer NCT07042802
Em recrutamento
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). NCT05116189
Ativo, não recrutandoResultados publicados
A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer NCT06890858
Em recrutamento
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer NCT06394492
Em recrutamento
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer NCT03519230
Ativo, não recrutando
Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer NCT06019923
Em recrutamento
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer NCT05737303
Em recrutamento
Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen NCT06251947
Em recrutamento
Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments NCT06799637
Em recrutamento
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial NCT05607329
Em recrutamento
SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors NCT06562647
Em recrutamento
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer NCT06014190
Em recrutamento
Retrospective Study of Brachytherapy (RetroBT) NCT05242861
Em recrutamento
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) NCT02859038
Ativo, não recrutando
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors NCT05518253
Em recrutamento
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors NCT06380660
Em recrutamento
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors. NCT04778839
Em recrutamento
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) NCT05445778
Em recrutamento
Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer NCT05633199
Ainda não recrutando
APG-2449 in Patients With Advanced Solid Tumors NCT03917043
Em recrutamento
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer NCT05551507
Em recrutamento
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors NCT05914116
Em recrutamento
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer NCT05200260
Em recrutamento
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) NCT03983226
Em recrutamento
A Clinical Study on the Feasibility and Safety of Abdominal Endoscopic Single-port Surgery System to Assist Gynecological Day Surgery NCT06828419
Ainda não recrutando
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (MK-2870-001) NCT04152499
Ativo, não recrutando
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (panSOHO) NCT06760819
Em recrutamento
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) (DO-01) NCT06819007
Em recrutamento
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors NCT04895709
Em recrutamento
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (FRAmework-01) NCT07213804
Em recrutamento
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (RAINFOL-02) NCT06619236
Ativo, não recrutando
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT06161025
Em recrutamento
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy NCT01874353
Ativo, não recrutandoResultados publicados
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors NCT06607185
Ativo, não recrutando
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1) NCT01844986
Ativo, não recrutandoResultados publicados
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) NCT02568267
Ativo, não recrutando